Patients with DM who are MDA5 antibody negative are noted to have a higher IFN 1 signature in muscle [13], which may explain the rapid improvement in myopathic symptoms in our patient after anifrolumab therapy. The gene discussed is IFIH1; the disease is dermatomyositis.